Neogenomics, Inc.
NEO
$7.42
$0.294.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.31% | 2.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.31% | 2.49% | |||
| Cost of Revenue | 0.05% | 1.94% | |||
| Gross Profit | -5.19% | 3.17% | |||
| SG&A Expenses | 6.70% | 4.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.24% | 3.30% | |||
| Operating Income | -75.03% | -12.94% | |||
| Income Before Tax | -59.08% | 9.64% | |||
| Income Tax Expenses | 133.08% | -436.00% | |||
| Earnings from Continuing Operations | -69.17% | 13.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -69.17% | 13.42% | |||
| EBIT | -75.03% | -12.94% | |||
| EBITDA | -540.72% | -41.41% | |||
| EPS Basic | -68.88% | 13.56% | |||
| Normalized Basic EPS | -87.91% | -26.89% | |||
| EPS Diluted | -68.88% | 13.93% | |||
| Normalized Diluted EPS | -87.91% | -26.89% | |||
| Average Basic Shares Outstanding | 0.17% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||